Christopher Benecchi Sage Therapeutics, Inc. (SAGE) insider trading activity

Christopher Benecchi is Chief Operating Officer of Sage Therapeutics, Inc.. Currently has a direct ownership of 0 shares of SAGE, which is worth approximately $0. The most recent transaction as insider was on Jul 31, 2025, when has been sold 64,428 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

100.0% 3M change

100.0% 12M change

Total Value Held $0

Christopher Benecchi Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 31 2025	SELL Sale (or disposition) back to the issuer	-	64,428 Reduced 100.0%	0 Common Stock
Feb 13 2025	SELL Payment of exercise price or tax liability	$5,901 $7.18 p/Share	822 Reduced 1.84%	43,915 Common Stock
Jan 16 2025	BUY Grant, award, or other acquisition	-	20,000 Added 30.89%	44,737 Common Stock
Nov 01 2024	BUY Grant, award, or other acquisition	-	6,250 Added 20.17%	24,737 Common Stock
Aug 05 2024	SELL Payment of exercise price or tax liability	$42,604 $8.96 p/Share	4,755 Reduced 20.46%	18,487 Common Stock
Aug 05 2024	BUY Grant, award, or other acquisition	-	16,200 Added 41.07%	23,242 Common Stock
Feb 13 2024	BUY Grant, award, or other acquisition	-	13,500 Added 41.0%	19,430 Common Stock
Feb 03 2023	SELL Payment of exercise price or tax liability	$93,575 $44.16 p/Share	2,119 Reduced 28.72%	5,260 Common Stock
Feb 03 2023	BUY Grant, award, or other acquisition	-	6,750 Added 47.77%	7,379 Common Stock

Christopher Benecchi

Chief Operating Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SAGE shares.

Notify only if

Value

Insider Trading

Get notified when an Sage Therapeutics, Inc. insider buys or sells SAGE shares.

Notify only if

Operation

Value

Type

News

Receive news related to Sage Therapeutics, Inc.

Track Activities on SAGE

Account